SU-C-201-05: Silicon Array Dosimeter in Situ with Electronic Portal Image Device for Simultaneous Transit Dose and Image Verification in Radiotherapy




To investigate an Electronic Portal Imaging Device (EPID) coupled to a 2D array dosimeter to provide simultaneous imaging and dose verification.


The novel dual detector configuration comprised of a 2D diode array dosimeter, referred to as a Magic Plate (MP) placed directly on a standard EPID. Dose response of the MP was evaluated by measuring the detector's response with respect to off-axis position and field size with 30 cm of solid water (SW) acting as a transit object in the beam. Measurements were performed with 3, 5, 10 and 15 mm SW build-up and compared to 2D ionisation chamber array (ICA) measurements and the PinnacleTM treatment planning system (TPS) at a source to detector distance of 150 cm with a 6 MV beam. Clinical dosimetric performance was evaluated by measuring a number of intensity-modulated radiation therapy (IMRT) beams in transit geometry. Imaging performance of the EPID was quantified by measuring the contrast-to-noise ratio (CNR) and spatial resolution. Images of a Rando phantom were used for qualitative assessment.


Measured MP off-axis and field size response agreed within 2% of TPS and ICA responses when measured using 15 mm SW build-up. Clinical IMRT beams had gamma pass rates of ≥95% at 3%/3mm criteria. Measured CNR and spatial resolution (f50) were 264.96, 210.6, and 0.41, 0.40 with build-up of 5 and 15 mm respectively for the dual detector configuration. CNR and spatial resolution of 643.9 and 0.41 were measured for standard EPID. CNR was quantitatively worse in the dual detector configuration. Differences in imaging performance were not visible in a qualitative assessment using a Rando phantom.


Combining a prototype MP 2D dosimeter with a conventional EPID did not significantly detract from the performance of either device and has the potential for simultaneous on-line patient transit dosimetry and image assessment in radiation therapy.

Cancer Institute NSW Australia(Research Equipment Grant 10/REG/1-20) and Cancer Council NSW (Grant ID RG 1-06)